Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ELUT Stock Forecast 2026-2027
$0.69
Current Price
$29.42M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ELUT Price Targets
+626.1%
To High Target of $5.00
+408.3%
To Median Target of $3.50
+190.4%
To Low Target of $2.00
ELUT Price Momentum
+9.5%
1 Week Change
-1.4%
1 Month Change
-78.0%
1 Year Change
0.0%
Year-to-Date Change
-80.1%
From 52W High of $3.46
+37.7%
From 52W Low of $0.50
📊 TOP ANALYST CALLS
Did ELUT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Elutia is one of their latest high-conviction picks.
Latest ELUT Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, ELUT has a bullish consensus with a median price target of $3.50 (ranging from $2.00 to $5.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.69, the median forecast implies a 408.3% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ross Osborn at Cantor Fitzgerald, projecting a 626.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELUT Analyst Ratings
2
Buy
0
Hold
0
Sell
ELUT Price Target Range
Low
$2.00
Average
$3.50
High
$5.00
Current: $0.69
Latest ELUT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELUT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 10, 2025 | Lake Street | Frank Takkinen | Buy | Maintains | $6.00 |
| May 9, 2025 | Lake Street | Frank Takkinen | Buy | Maintains | $8.00 |
| Mar 7, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $8.00 |
| Nov 15, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $10.00 |
| Sep 6, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $10.00 |
| Aug 8, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $10.00 |
| Jun 21, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $10.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $11.00 |
| Jun 18, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $11.00 |
| May 10, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $5.00 |
| Nov 14, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $6.00 |
| Sep 28, 2023 | Lake Street | Frank Takkinen | Buy | Initiates | $3.00 |
| Sep 26, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $8.00 |
| Sep 19, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $8.00 |
| Aug 15, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| May 12, 2023 | Cantor Fitzgerald | Brandon Folkes | Overweight | Maintains | $10.00 |
| Nov 16, 2022 | Truist Securities | Kaila Krum | Buy | Maintains | $10.00 |
| Nov 15, 2022 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $10.50 |
| Mar 4, 2022 | Cowen & Co. | Josh Jennings | Outperform | Maintains | $13.00 |
| Nov 2, 2020 | Truist Securities | Buy | Initiates | $N/A |
Elutia Inc. (ELUT) Competitors
The following stocks are similar to Elutia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Elutia Inc. (ELUT) Financial Data
Elutia Inc. has a market capitalization of $29.42M with a P/E ratio of -0.4x. The company generates $21.75M in trailing twelve-month revenue with a -121.7% profit margin.
Revenue growth is -9.3% quarter-over-quarter, while maintaining an operating margin of -131.1% and return on equity of +116.6%.
Valuation Metrics
Market Cap
$29.42M
Enterprise Value
$55.29M
P/E Ratio
-0.4x
PEG Ratio
0.0x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
-9.3%
Gross Margin
+55.8%
Operating Margin
-131.1%
Net Margin
-121.7%
EPS Growth
-43.9%
Financial Health
Cash/Price Ratio
+16.1%
Current Ratio
0.4x
Debt/Equity
-0.7x
ROE
+116.6%
ROA
-36.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Elutia Inc. (ELUT) Business Model
About Elutia Inc.
What They Do
Develops drug-eluting biomaterials for healthcare.
Business Model
Elutia Inc. generates revenue through the commercialization of its innovative drug-eluting biomaterials, which are designed for targeted delivery of pharmaceuticals in various medical applications such as wound care and cardiovascular treatments. The company focuses on enhancing therapeutic efficacy while minimizing side effects, making its products appealing to healthcare providers and patients alike.
Additional Information
Elutia is positioned in the growing field of precision medicine, utilizing advanced biomaterial technologies to improve patient outcomes. Its role in medical innovation underscores its potential impact on the healthcare industry by providing safer and more effective therapeutic solutions.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
51
CEO
Dr. C. Randal Mills Ph.D.
Country
United States
IPO Year
2020
Website
elutia.comElutia Inc. (ELUT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
ELUTIA INC (ELUT) Upgraded to Buy: Here's What You Should Know
ELUTIA INC (ELUT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Dec 31, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Elutia Inc. reported a 16% increase in Q4 revenue year-over-year, eliminated $26.9M of secured debt, and ended the year with $44.3M in cash and escrowed proceeds.
Why It Matters
Strong revenue growth and debt reduction enhance Elutia's financial health, while significant cash reserves support future development, potentially boosting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The company will present on Tuesday, January 13th, at 10:00 a.m. PT / 1:00 p.m. ET.
Why It Matters
The company's upcoming presentation may reveal key insights or strategic updates, potentially impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ELUTIA INC (ELUT) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects.
Why It Matters
Growing optimism and a Zacks Rank #2 upgrade indicate potential for increased earnings, suggesting ELUT's stock may rise, attracting investor interest and confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Elutia Inc. (ELUT) Q3 2025 Earnings Call Transcript
2 months ago
Quick Summary
Elutia Inc. (ELUT) will hold its Q3 2025 earnings call on November 6, 2025, at 5:00 PM EST, featuring CEO C. Mills and CFO Matthew Ferguson.
Why It Matters
Elutia's Q3 2025 earnings call provides insights into financial performance and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
NXT-41x is advancing to meet a significant need in the $1.5 billion U.S. plastic and reconstructive surgery market. A conference call is scheduled for today at 5:00 p.m. ET.
Why It Matters
NXT-41x targets a $1.5 billion market in plastic and reconstructive surgery, indicating strong growth potential and revenue opportunities for investors in the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Elutia Inc. (Nasdaq: ELUT) will release its Q3 2025 financial results on November 6, 2025, after market close, followed by a conference call at 5 PM ET.
Why It Matters
Elutia Inc.'s upcoming financial results release could significantly impact its stock price, providing insights into its performance and future growth potential in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ELUT Stock
What is Elutia Inc.'s (ELUT) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Elutia Inc. (ELUT) has a median price target of $3.50. The highest price target is $5.00 and the lowest is $2.00.
Is ELUT stock a good investment in 2026?
According to current analyst ratings, ELUT has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELUT stock?
Wall Street analysts predict ELUT stock could reach $3.50 in the next 12 months. This represents a 408.3% increase from the current price of $0.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Elutia Inc.'s business model?
Elutia Inc. generates revenue through the commercialization of its innovative drug-eluting biomaterials, which are designed for targeted delivery of pharmaceuticals in various medical applications such as wound care and cardiovascular treatments. The company focuses on enhancing therapeutic efficacy while minimizing side effects, making its products appealing to healthcare providers and patients alike.
What is the highest forecasted price for ELUT Elutia Inc.?
The highest price target for ELUT is $5.00 from Ross Osborn at Cantor Fitzgerald, which represents a 626.1% increase from the current price of $0.69.
What is the lowest forecasted price for ELUT Elutia Inc.?
The lowest price target for ELUT is $2.00 from at , which represents a 190.4% increase from the current price of $0.69.
What is the overall ELUT consensus from analysts for Elutia Inc.?
The overall analyst consensus for ELUT is bullish. Out of 7 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.50.
How accurate are ELUT stock price projections?
Stock price projections, including those for Elutia Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 1:45 PM UTC